Fore Pharma, Jan 2012, Pages: 13
Fore Pharma’s latest report ‘Global Head and NeckCancerDrugPipeline Capsule – 2012’ is an outline of all the key research and development (R&D) activities of the global head and neckcancerdrug
Fore Pharma, Aug 2011, Pages: 13
Fore Pharma’s latest report ‘Global Head and NeckCancerDrugPipeline Capsule – 2011’ is an outline of all the key research and development (R&D) activities of the global head and neckcancerdrug
GBI Research, Dec 2011, Pages: 215
, ovarian cancer, cervical cancer and head and neckcancer. The report also includes insights into the oncology therapeutics R&D pipeline. It analyzes the competitive landscape in the oncology therapeutics
GBI Research, March 2011, Pages: 120
include colorectal cancer, prostate cancer, head and neckcancer and ovarian cancer. The report includes analysis of endpoints of major oncological market products and profiles. In addition to marketed
Bioseeker, Oct 2010, Pages: 659
the cancer vaccine pipeline and discern the level of competition in fine detail.
Major Findings from this report:
- The identified competitive landscape of cancer vaccine drugs is split between the 46% which
Life Science Analytics, March 2011, Pages: 497
Head and NeckCancer Therapy Area PipelineReport contains detailed information on the head and neckcancerdrugpipeline. This report provides insight into the pipeline status of head and neck
GlobalData, Nov 2010, Pages: 5
Eli Lilly Drops Plans to Seek Approval For its Established Drug Alimta as a Treatment For Head And NeckCancer
Summary
Our report, “Eli Lilly Drops Plans to Seek Approval For its Established Drug
Business Insights, June 2011, Pages: 164
cancer Overview Diagnosis, treatment, and management Epidemiology Forecast epidemiology Lymphomas Overview Diagnosis, treatment, and management Epidemiology Forecast epidemiology Head and neck
Bioseeker, Nov 2010, Pages: 777
: Cancer Highlights’™ Five Pillar Drug Assessment
Table 2: Breakdown of the Included Cancer Vaccine DrugPipeline by Stage of Development
Table 3: Head to Head Target Competition among Cancer Vaccine Drugs
GlobalData, Jan 2010, Pages: 51
Head and NeckCancer - DrugPipeline Analysis and Market Forecasts to 2016
Summary
GlobalData, the industry analysis specialist, has released its new report, “Head and NeckCancer - DrugPipeline
Bioseeker, June 2007, Pages: 172
Table 86: Antibody Pipeline by Targets in Head and NeckCancer
Table 87: Antibody Pipeline by Targets in Leukemias
Table 88: Antibody Pipeline by Targets in Liver Cancer
Table 89: Antibody Pipeline
GBI Research, Sep 2010, Pages: 78
for cancer biomarkers and provides comprehensive analysis. The report also looks into the cancer biomarkers pipeline along with analysis on the pipeline by indication, phase of development and geography
Global Industry Analysts, Inc., Oct 2011, Pages: 897
. For instance, use of radiation therapy, surgery and chemotherapy for treating neck and headcancers could affect the head and neck arrangement and make eating, swallowing and breathing difficult. Therefore
Bioseeker, Nov 2011, Pages: 906
Development Profiles of Peptide Drugs for the Treatment of Gastrointestinal Stomach Cancer
Table 55: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Head and NeckCancer
Table 56
Bioseeker, Sep 2011, Pages: 1944
to stratify the antibody drugpipeline in oncology and discern the level of competition in fine detail.
Major Findings from this report:
- The identified competitive landscape of antibody drugs in cancer
Bioseeker, Sep 2010, Pages: 1227
CancerPipeline of Angiogenesis Affecting Drugs by Stage of Development
Table 3: Head to Head Target Competition among Angiogenesis Affecting Drugs in Cancer
Table 4: Overview of Drug Target Strategy
Jain PharmaBiotech, Feb 2012, Pages: 864
biomarkers
Metabolomic biomarkers of cancer
Choline phospholipid biomarkers of cancer
Hypoxia-inducible factor-1
Detection of drug resistance in cancer by metabolic profiling
Epitomics for the early
Bioseeker, June 2010, Pages: 596
Highlights’™ Five Pillar Assessment
Table 2: Breakdown of the Included Cancer Peptide Pipeline by Stage of Development
Table 3: Head to Head Target Competition among Cancer Peptide Drugs
Table 4: Overview
Bioseeker, Dec 2011, Pages: 1617
for the Treatment of Gastrointestinal Stromal Cancer
Table 92: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Head and NeckCancer
Table 93: The Competition through Close Mechanistic
Bioseeker, Jan 2012, Pages: 1704
Mechanistic Approximation between Gastrointestinal Stromal CancerDrugs
Table 93: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Head and NeckCancer
Table 94
